International Journal of Hypertension / 2012 / Article / Tab 1

Clinical Study

Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension

Table 1

Baseline characteristics.

T80/H25V160/H25Placebo

N32831780
Age, years (SD)57.0 (10.7)56.0 (9.7)56.4 (10.6)
Age group, N (%)
 <65 years255 (77.7)261 (82.3)63 (78.8)
 ≥65 years73 (22.3)56 (17.7)17 (21.3)
Gender, N (%)
 Male181 (55.2)176 (55.5)43 (53.8)
 Female147 (44.8)141 (44.5)37 (46.3)
Race, N (%)
 Non-Black241 (73.5)230 (72.6)57 (71.3)
 Black87 (26.5)87 (27.4)23 (28.8)
BMI, kg/m2 (SD)31.4 (6.1)31.8 (6.8)31.5 (6.2)
SBP, mm Hg (SD)167.6 (5.4)168.3 (5.9)167.1 (5.8)
DBP, mm Hg (SD)103.2 (4.4)103.4 (4.8)103.3 (4.0)
Pulse rate, beats/min (SD)75.7 (9.9)75.0 (9.4)74.5 (8.8)

BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; SD: standard deviation; T80/H25: telmisartan 80 mg/hydrochlorothiazide 25 mg; V160/H25: valsartan 160 mg/hydrochlorothiazide 25 mg.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.